tbuckley/cabot-search huggingface dataset:
P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis
Authors: G. Caira, M. Calegari, A. Anghelone, J. Lucchetti, E. Dell’Aquila, C. Signorelli, A. Spring, R. Saltarelli, A. Cosimati, I. Zurlo, L. Angotti, F. Schietroma, C. Pozzo, L. Chiofalo, F. Santamaria, C. Morelli, F. Zoratto, M. Schirripa, L. Salvatore, M. Basso, G. Tortora
Journal: Annals of Oncology (2023)
P-32 Risk factors for early recurrence after radical gastrectomy followed by adjuvant chemotherapy for stage II or III gastric cancer: A multicenter, retrospective study
Authors: S. Yagi, K. Kumagai, S. Nunobe, N. Ishizuka, T. Yamaguchi, Y. Imai, M. Tsuda, S. Haruta, H. Fukunaga, T. Yamada, M. Goto
Journal: Annals of Oncology (2023)
P-184 Demographic and clinicopathologic factors in patients with hepatocellular carcinoma in Latin American population
Authors: G. Calderillo-Ruiz, S. Zilli-Hernandez, A. Camacho-Sanchez, B. Carbajal-López, M. Herrera, E. Ruiz-Garcia, S. Miyagui Adame, E. García-García, C. Diaz
Journal: Annals of Oncology (2023)
O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577
Authors: R. Kelly, M. Moehler, J. Ajani, J. Yao, J. Kuzdzal, T. Zander, E. Van Cutsem, G. Piessen, G. Mendez, J. Feliciano, S. Motoyama, A. Lièvre, H. Uronis, E. Elimova, C. Grootscholten, K. Geboes, Y. Yang, J. Zhang, R. Novosiadly, J. Cleary, M. Lei
Journal: Annals of Oncology (2023)
SO-33 The effect of RAS/BRAF mutation status on survival and treatment efficacy in vulnerable older patients with metastatic colorectal cancer – a post-hoc exploratory analysis of the randomized NORDIC9-study
Authors: G. Liposits, R. Jesper, S. Winther, H. Skuladottir, S. Möller, E. Hofsli, C. Shah, L. Poulsen, None î Berglund, C. Qvortrup, P. Osterlund, B. Glimelius, H. Sorbye, P. Pfeiffer
Journal: Annals of Oncology (2023)
SO-30 RAS status in circulating-tumor DNA after chemotherapy in RAS-mutant mCRC: The RASMEX study (JACCRO CC-17)
Authors: S. Nishina, N. Izawa, M. Watabe, T. Matsumoto, M. Kataoka, A. Sugaya, T. Kashiwada, E. Oki, A. Makiyama, Y. Yaguchi, T. Ohta, T. Toyokawa, Y. Miura, K. Kobayashi, Y. Kito, O. Muto, Y. Kagawa, H. Satake, M. Takeuchi, W. Ichikawa, M. Fujii, Y. Sunakawa
Journal: Annals of Oncology (2023)
PD-15 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments
Authors: M. Persano, M. Rimini, T. Toshifumi, G. Suda, S. Shigeo, M. Kudo, J. Cheon, F. Finkelmeier, J. Presa, G. Masi, C. Yoo, S. Lonardi, F. Tovoli, F. Piscaglia, M. Iavarone, F. Marra, E. Tamburini, G. Cabibbo, M. Scartozzi, A. Casadei-Gardini
Journal: Annals of Oncology (2023)
P-288 Real-world experience of immune checkpoint inhibitors in MSI-H/dMMR metastatic colorectal cancer in a tertiary cancer center in Saudi Arabia
Authors: R. Ajina, A. Alhareeri, W. Philip, N. Alsekait, N. Alarifi, H. Alismail, S. Alshieban, B. Almuzzaini, K. Alshammari
Journal: Annals of Oncology (2023)
SO-17 A new risk classification integrating ctDNA, CEA, and pTN stage for DFS prognosis and predictive value for treatment duration in stage III colon cancer
Authors: T. Samaille, A. Falcoz, R. Cohen, T. André, P. Laurent Puig, J. Taieb, E. Auclin, D. Vernerey
Journal: Annals of Oncology (2023)
P-173 Extended molecular profiling in patients with biliary tract cancers: Impact of the BRCAness phenotype in patients management
Authors: V. Genovesi, C. Vivaldi, C. Congregati, M. Caccese, F. Salani, V. Massa, L. Bernardini, S. Cesario, S. Romano, D. Berra, J. Graziani, L. Bartalini, G. Grelli, V. Caputo, E. Vasile, L. Fornaro, B. Toschi, G. Masi
Journal: Annals of Oncology (2023)
P-349 An evidence-based patient resource program to improve the everyday lives of patients with metastatic gastrointestinal cancer
Authors: A. Sobrero, D. Chuter, T. Gruenberger, M. Juznic, K. Meier, L. Monje-Garcia, B. Moss, M. Moss, V. Neves, I. Rawicka, P. Rzadkowska, J. Tamminen, Z. Maravic
Journal: Annals of Oncology (2023)
O-11 The genomic landscape of appendiceal adenocarcinoma revealed by 855 whole exome sequences
Authors: M. White, B. Helmink, S. Rivero-Hinojosa, A. Yousef, N. Bhutiani, V. Aushev, S. Chowdhury, A. Jurdi, M. Liu, K. Fournier, J. Shen
Journal: Annals of Oncology (2023)
PD-7 Osemitamab plus capecitabine and oxaliplatin (CAPOX) as the first-line treatment of advanced G/GEJ cancer – updated efficacy data per claudin 18.2 expression level from study TranStar102/TST001-1002-cohort C
Authors: L. Shen, D. Liu, N. Li, W. Guo, T. Liu, H. Li, J. Li, F. Zhao, M. Sun, Y. Bai, Y. Deng, Z. Zhuang, Q. Fan, L. Han, S. Xia, X. Zhu, C. Qi, L. Xu, X. Qian, C. Germa
Journal: Annals of Oncology (2023)
P-386 Novel data visualization and unsupervised machine learning techniques to support optimal management of toxicity profiles of encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer
Authors: H. Wasan, S. Lonardi, J. Desai, G. Folprecht, C. Gallois, E. Polo Marques, S. Khan, J. Murris, J. Taieb
Journal: Annals of Oncology (2023)
SO-2 Quantitative risk-benefit assessment of ivosidenib compared to placebo in patients with IDH1-mutated intrahepatic cholangiocarcinoma: Phase 3 ClarIDHy trial
Authors: J. Valle, G. Abou-Alfa, R. Kelley, M. Lowery, R. Shroff, Y. Bian, G. Saint-Hilary, H. Liu, Z. Teng, Z. Hua, C. Gliser, A. Vogel, M. Javle
Journal: Annals of Oncology (2023)
P-38 Using a machine learning approach to study host-microbiome interactions in early-onset colorectal adenocarcinoma
Authors: T. Jayakrishnan, N. Sangwan, S. Barot, N. Farha, A. Mariam, S. Xiang, F. Aucejo, M. Conces, K. Nair, S. Krishnamurthi, S. Schmit, D. Liska, D. Rotroff, A. Khorana, S. Kamath
Journal: Annals of Oncology (2023)
P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer
Authors: A. Oaknin, F. Meric-Bernstam, J. Lang, K. Ciombor, I. Ray-Coquard, A. Oza, K. Yonemori, R. Xu, J. Zhao, S. Gajavelli, J. Filant, T. Hovey, Y. Janjigian
Journal: Annals of Oncology (2023)
P-275 FOLFOX versus FOLFIRI as second-line treatment after cisplatin-gemcitabine in patients with advanced biliary tract cancers
Authors: F. Nichetti, M. Rizzato, M. Bensi, F. Salani, A. Franza, V. Piva, R. Cerantola, M. Chiaravalli, G. Masi, S. Ahcene Djaballah, D. Barone, C. Vivaldi, F. Bergamo, S. Rota, M. Di Bartolomeo, F. de Braud, M. Niger, S. Lonardi
Journal: Annals of Oncology (2023)
O-4 GEMSTONE-304: A phase 3 study of sugemalimab plus chemotherapy versus chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)
Authors: J. Li, Z. Chen, Y. Bai, B. Liu, Q. Li, J. Zhou, J. Zhang, T. Deng, F. Zhou, S. Gao, S. Yang, F. Ye, L. Chen, W. Bai, X. Yin, Y. Xu, J. Hu, J. Ni, B. Wang, J. Yang
Journal: Annals of Oncology (2023)
P-177 Italian real world artificial intelligence (AI) based analysis of EaRly-onset COLorEctal cancer: The ERCOLE study
Authors: M. Calegari, L. Salvatore, L. Mastrantoni, J. Lenkowicz, C. Iacomini, N. Di Giorgi, S. Alfieri, D. D'Ugo, R. Persiani, L. Sofo, G. Sganga, S. Agnes, F. Pacelli, C. Coco, M. Bensi, A. Anghelone, M. Basso, C. Pozzo, V. Valentini, G. Tortora
Journal: Annals of Oncology (2023)
SO-18 ctDNA-guided adjuvant treatment after radical intent treatment of metastatic spread from colorectal cancer is feasible – results from the preplanned interim analysis of the OPTIMISE study
Authors: L. Callesen, T. Hansen, R. Andersen, N. Pallisgaard, S. Kramer, S. Schlander, S. Rafaelsen, A. Boysen, L. Jensen, A. Jakobsen, K. Spindler
Journal: Annals of Oncology (2023)
P-228 Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer: SWOG S2107
Authors: V. Morris, K. Guthrie, S. Kopetz, R. Breakstone, T. Karasic, Z. Hu, S. Colby, M. Fakih, S. Gholami, P. Gold, E. Chiorean, P. Philip
Journal: Annals of Oncology (2023)
P-253 Single agent immunotherapy in advanced oesophago-gastric (OG) cancer: An option for frail patients
Authors: G. Patel, M. Khan, B. Russell, S. San Ti, A. Mattar, K. Srikandarajah, M. Van Hemelrijck, S. Ngan, N. Maisey, A. Sita-Lumsden
Journal: Annals of Oncology (2023)
P-201 First large cohort in Latin America of CCR BRAF V600E mutated. Real world data
Authors: G. Catani, R. Luca, A. Oviedo, L. Bruno, F. Esteso, A. Rodriguez, D. Enrico, F. Waisberg, E. Slutsky, G. Mendez, M. Chacón, J. O’Connor
Journal: Annals of Oncology (2023)
P-241 Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil plus bevazicumab: Final analysis from a Danish randomised study
Authors: P. Pfeiffer, S. Winther, S. Möller, L. Poulsen, M. Yilmaz, C. Qvortrup
Journal: Annals of Oncology (2023)
P-153 Focus on RAS codon 61 mutations in metastatic colorectal cancer (mCRC): A retrospective analysis
Authors: F. Schietroma, A. Anghelone, G. Valente, V. Beccia, G. Caira, A. Spring, G. Trovato, A. Di Bello, A. Ceccarelli, L. Chiofalo, S. Perazzo, M. Bensi, M. Basso, C. Pozzo, L. Salvatore, M. Calegari, G. Tortora
Journal: Annals of Oncology (2023)
P-99 Tumor treating fields (TTFields) are effective for treatment of gastric cancer cells, boosting the activity of FOLFOX
Authors: N. Flint-Brodsly, E. Zeevi, H. Fishman, H. Ene, A. Martinez-Conde, R. Frechtel-Gerzi, K. Wainer-Katsir, E. Dor-On, Y. Porat, T. Voloshin, A. Haber, M. Giladi, U. Weinberg, Y. Palti
Journal: Annals of Oncology (2023)
P-374 Total neoadjuvant treatment of rectal cancer by MRI-guided radiotherapy
Authors: M. De Ridder, J. Bezuidenhout, J. Van Loon, N. Platteaux, T. Everaert, A. Bom, E. Van Eetvelde, K. Kortbeek, A. Sermeus, A. de Haar-Holleman, S. Van Laere, I. Dufait, T. Gevaert
Journal: Annals of Oncology (2023)
P-343 The impact of genomic alterations on response rate and survival outcomes in advanced BTC patients who receive cisplatin/gemcitabine plus durvalumab in clinical practice
Authors: M. Rimini, M. Rizzato, L. Rimassa, M. Niger, L. Fornaro, L. Antonuzzo, E. Martinelli, I. Garajová, A. Pastorino, G. Giordano, M. Schirripa, M. Silletta, A. Diana, A. Casadei Gardini
Journal: Annals of Oncology (2023)
P-165 First-line treatment with CET/PAN vs. BEV in elderly patients with RAS WT mCRC: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Authors: K. Yamamoto, T. Hirose, A. Takashima, K. Yamazaki, H. Yukami, H. Uetake, M. Tsuda, T. Suto, T. Moriwaki, N. Sugimoto, H. Ojima, Y. Takii, H. Yasui, T. Esaki, A. Tsuji, M. Goto, R. Sawada, S. Otsu, K. Shinozaki, K. Nagashima, Y. Shimada
Journal: Annals of Oncology (2023)
P-345 SOX-2 promotes epithelial-to-mesenchymal transition by modulating SLUG expression in esophageal squamous cells
Authors: S. Jayaraman, J. Pazhani, V. Veeraraghavan, V. Raghavan Pillai, J. Rebecca Roy, C. Janaki, P. Rajagopal, V. Prabhu
Journal: Annals of Oncology (2023)
SO-10 Phase 2 study of futibatinib in patients with specific FGFR aberrations: Activity in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplification
Authors: T. Satoh, P. Barthélémy, L. Nogova, K. Honda, S. Iwasa, K. Lee, S. Rha, J. Ajani, N. Hangai, S. Liu, J. Kremer, M. Mina, K. Shitara
Journal: Annals of Oncology (2023)
P-69 Efficacy and safety of surufatinib in intrahepatic cholangiocarcinoma: Preliminary results of a real-world study
Authors: Z. Zhang, Y. Xu, K. Li, J. Lu, X. Zhou, F. Yang, G. Bao, C. Ma, E. Li, Y. Gao, Q. He, K. Sun
Journal: Annals of Oncology (2023)
P-64 Retrospective analysis of radical surgeries on deficient mismatch repair metastatic colorectal cancer with durable partial responses under checkpoint inhibitors. Is radical surgery still necessary?
Authors: C. Torrado, F. Tallafigo, E. Monescillo, A. López Ladrón, R. Pérez Velasco, P. Macías Rodríguez, J. Rodriguez, A. Barroso, I. Gallego Jimenez, L. Limon, M. Valladares-Ayerbes
Journal: Annals of Oncology (2023)
P-277 Real-world efficacy, safety, and impact of the GIPI score of nivolumab in advanced esophageal squamous cell carcinoma (ESCC) refractory or intolerant to prior chemotherapy in European population: The EPIC trial
Authors: N. Martínez Lago, A. Cousillas Castiñeiras, P. Gonzalez Villarroel, A. Fernández-Montes, A. Carral Maseda, M. Costa Rivas, M. Reboredo-Lopez
Journal: Annals of Oncology (2023)
O-5 Integrating trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2+ gastric cancer (GC) - subgroup analyses of EORTC 1203 “INNOVATION”, a collaboration with KCSG and DUCG
Authors: A. Wagner, H. Grabsch, M. Mauer, S. Lorenzen, O. Bouché, P. Thuss-Patience, A. Elme, M. Moehler, U. Fumagalli Romario, Y. Kang, G. Folprecht, U. Martens, M. Galán Guzmán, M. Ducreux, M. Díez García, G. Piessen, M. Collienne, F. Lordick
Journal: Annals of Oncology (2023)
P-127 The screening and consensus based on practices and evidence (SCOPE) survey – results of a real-world survey on practice patterns in gastric cancer
Authors: E. Smyth, D. Modest, G. Prager, D. Santini, F. Rivera, J. Phelip, M. Dioca, H. Wasan, S. Boeck, A. Zaanan
Journal: Annals of Oncology (2023)
P-265 Value of the Glasgow Prognostic Score (GPS) in the prognosis of hospitalised patients with gastrointestinal cancer
Authors: J. Peña, A. Rueda-Lara, G. Martin-Montalvo, M. Alameda, D. Jimenez-Bou, I. Ruiz-Gutierrez, R. Marcano, A. Garcia-Leal, P. Zwisler Contreras, D. Martinez Perez, D. Viñal, J. Perez-Wert, A. Custodio, I. Ghanem, N. Rodríguez-Salas, J. Feliu, L. Ruiz-Giménez, D. Sanchez
Journal: Annals of Oncology (2023)
P-92 Is preoperative chemosensitivity associated with improved outcomes in locally advanced gastric cancer? A multicentric retrospective real-world study
Authors: T. Caleça, M. Honório, M. Sousa, J. Ribeiro, A. Fortuna, D. Neto da Silva, J. Albuquerque, M. Menezes, C. Trabulo, D. Costa
Journal: Annals of Oncology (2023)
P-327 Comparison of clinicopathological and molecular features of two rare entities: Appendiceal carcinoma and small bowel adenocarcinoma
Authors: K. Vega-Cano, S. Bueno, J. Hernando, A. García Álvarez, O. Mirallas, J. Ucha Hermida, C. Salva de Torres, G. Molina Lores, D. Gómez-Puerto, P. Mascaro, J. Yaringaño, P. Benito, J. Sanchez Garcia, J. Capdevila
Journal: Annals of Oncology (2023)
P-135 Detection of RAS gene mutations in patients with metastatic colorectal cancer during cetuximab-based first-line treatment and survival of the patients in relation to changes in RAS gene status
Authors: M. Stresko, R. Behulova, L. Sebest, R. Valencikova, D. Plancikova, J. Melichova, V. Usakova, M. Dienerova, E. Grmanova, V. Vaclav, M. Drahokoupilova, M. Novisedlakova, M. Fremal, B. Puskarova, O. Szegheova, O. Rosinska, J. Detvay, J. Durkova, L. Pindesova, R. Gura, Z. Racayova, J. Chmelkova
Journal: Annals of Oncology (2023)
P-179 Prognostic and predictive value of CEA before initiation of therapy in the XELAVIRI trial
Authors: A. Alig, V. Heinemann, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, J. Uhlig, M. Schenk, C. Denzlinger, A. Stahler, S. Held, S. Stintzing, D. Modest, K. Heinrich
Journal: Annals of Oncology (2023)
P-214 Utility of “pseudo-adjuvant” chemotherapy (CT) in metastatic colorectal cancer (mCRC): A monocentric multidisciplinary experience
Authors: G. Arrivi, M. Roberto, F. Schipilliti, E. Paganoni, P. Mercantini, E. Pilozzi, M. Osti, E. Iannicelli, A. Tipaldi, F. Mazzuca
Journal: Annals of Oncology (2023)
P-316 A retrospective study of gemcitabine with nab-paclitaxel as third-line retreatment in advanced pancreatic adenocarcinoma
Authors: T. McSweeney, A. Das, A. O'Mahony, F. O'Tighearnaigh, L. O'Byrne, M. Feely, E. Passmore, S. Keane, S. Lanigan, S. Fitzgerald, T. Browne, V. De Beer, A. Dean
Journal: Annals of Oncology (2023)
P-304 CDH1 and CTNNA1 negative hereditary diffuse gastric carcinoma cases: Genetic susceptibility variants and their potential impacts
Authors: J. Ben Aissa-Haj, M. Kabbage, H. Guettiti Tounsi-Kettiti, S. Abdelhak, S. Boubaker, E. Rouleau
Journal: Annals of Oncology (2023)
P-292 The Meta-Lung score: Preoperative clinical score in lung-limited metastatic patients with colorectal cancer
Authors: P. Ziranu, P. Ferrari, F. Guerrera, P. Bertoglio, A. Tamburrini, P. Lyberis, A. Pretta, G. Grimaldi, E. Lai, M. Santoru, M. Dubois, L. Riva, F. Bardanzellu, V. Pusceddu, F. Mathieu, A. Alzetani, L. Luzzi, P. Solli, P. Paladini, E. Ruffini, R. Cherchi, M. Scartozzi
Journal: Annals of Oncology (2023)
P-267 Spatially resolved detection of premalignant lesions and immune-infiltration in gastric endoscopic biopsies using multiplexed immunofluorescence and correlation with OLGA/OLGIM assessment
Authors: F. Villarroel-Espindola, F. Vidal, A. Vargas, C. Barrientos, C. Podesta, K. Cereceda, R. Gonzalez-Stegmaier
Journal: Annals of Oncology (2023)
P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data
Authors: S. Ioannou, D. Zouki, V. Kardara, K. Exarchos, E. Arvanitou, K. Gkikas, N. Stavrou, G. Koronakis, I. Tourkantonis, A. Grivas, P. Kourakos, P. Gouveris, D. Kypreos, D. Korkolis, D. Tryfonopoulos, S. Demiri, G. Papaxoinis
Journal: Annals of Oncology (2023)
P-238 Real-life data on the use of FLOT4 and CROSS for patients with esophageal, gastric or gastroesophageal junction adenocarcinoma
Authors: I. Solana López, D. Gutierrez Abad, M. De Torres Olombrada, E. Martínez Moreno, I. Juez Martel, A. Martín Fernández de Soignie, C. de Zea Luque, N. Sánchez Baños, F. Escalona Martínez, B. Losada Vila, M. Pantin Gonzalez, L. Rodriguez Lajusticia, D. Malón Gimenez, B. Jiménez Munarriz, J. Guerra Martínez
Journal: Annals of Oncology (2023)
P-207 Analysis of chemotherapy-induced subtype shifts in patient-derived tumoroids and parallels to functional in-vitro chemosensitivity testing in pancreatic ductal adenocarcinoma
Authors: C. Nitschke, P. Walter, P. Schröder, C. Phan, M. Sinn, K. Jürgen, J. Izbicki, H. Wikman, F. Uzunoglu, T. Sturmheit
Journal: Annals of Oncology (2023)
P-167 Type 2 diabetes as a predictive and prognostic factor in advanced pancreatic cancer: Preliminary results of the Italian, observational PANCAKE study
Authors: F. Nichetti, A. Pretta, A. Franza, P. Andena, M. Puzzoni, G. Grelli, E. Lai, C. Pircher, S. Mariani, L. Bartalini, C. Vivaldi, M. Scartozzi, L. Mariani, M. Di Bartolomeo, F. de Braud, M. Niger
Journal: Annals of Oncology (2023)
P-297 Clinical characteristics and outcomes of patients with hepatocellular carcinoma treated at a large multidisciplinary clinic in Saudi Arabia
Authors: K. Alshammari, A. Alammar, A. Alrashdi, H. Alrajih, N. Algazlan, J. Altwalah, F. Alotaibi, H. Shehata, M. Alkaiyat, J. Al Qahtani, A. Alolayan, M. Arabi, M. Algarni
Journal: Annals of Oncology (2023)
P-90 Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAFV600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment
Authors: G. Vetere, M. Germani, M. Bensi, C. Antoniotti, S. Lonardi, A. Passardi, F. Ghelardi, M. Calegari, B. Borelli, S. Santucci, R. Intini, E. Cristarella, M. Persano, A. Puccini, D. Lavacchi, L. Noto, C. Zichi, R. Giampieri, M. Salati, C. Cremolini
Journal: Annals of Oncology (2023)
SO-14 Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup
Authors: A. Vogel, M. Kudo, S. Qin, Y. Chen, S. Li, F. Boisserie, R. Abdrashitov, R. Finn, T. Meyer, A. Zhu
Journal: Annals of Oncology (2023)
P-187 Targeting glutamine metabolism and EGFR in RAS wildtype colorectal cancer
Authors: K. Ciombor, J. Whisenant, G. Ayers, C. Eng, L. Goff, D. Cardin, T. Hickman, G. Smith, T. Peterson, S. Bae, S. Das, H. Manning, J. Berlin
Journal: Annals of Oncology (2023)
P-222 Prognostic value of skeletal muscle area at diagnosis in patients with metastatic colorectal cancer: A single institution experience
Authors: M. Rios, D. Viñal, A. Rueda-Lara, M. Alameda, G. Martin-Montalvo, N. Rodríguez-Salas, J. Feliu
Journal: Annals of Oncology (2023)
P-217 A retrospective, pathologist-based assessment of immunohistochemistry assay for CLDN18.2 expression in digestive system adenocarcinoma
Authors: M. Xu, C. Tan, X. Wang, X. Wang, W. Weng, M. Zhang, L. Wang, H. Sun, S. Ni, W. Sheng, D. Huang
Journal: Annals of Oncology (2023)
P-87 A multi-institutional observational study evaluating the efficacy of anti-epidermal growth factor antibody re-challenge in tissue RAS/BRAF wild-type metastatic colorectal cancer
Authors: R. Sawada, H. Osumi, Y. Yoshinami, A. Takashima, K. Ouchi, T. Wakatsuki, A. Ooki, I. Nakayama, S. Fukuoka, M. Ogura, D. Takahari, K. Chin, H. Hirano, H. Shoji, N. Okita, K. Kato, N. Ishizuka, M. Saruta, N. Boku, K. Yamaguchi, E. Shinozaki
Journal: Annals of Oncology (2023)
P-400 Validation study of a high-performance whole-blood assay for the detection of colorectal advanced adenomas in average risk population
Authors: S. Hosseinian, N. Hadadi, V. Wosika, S. Monnier-Benoit, L. Ciarloni, B. Hashemi, P. Romero, S. Tejpar
Journal: Annals of Oncology (2023)
P-19 Toxicity and outcome of definitive chemoradiotherapy for elderly patients with esophageal cancer
Authors: A. Iovashvili, L. Chkhaidze, E. Natelauri, B. Sokurashvili, E. Mariamidze, N. Kacheishvili, B. Jeremic, I. Kiladze
Journal: Annals of Oncology (2023)
PD-27 The use of pre-operative systemic oxaliplatin or irinotecan doublet chemotherapy in colorectal cancer peritoneal metastases (CRPM): Results from a single UK peritoneal tumour centre
Authors: N. Tinsley, R. Nagaraju, S. O'Dwyer, M. Braun, S. Mullamitha, K. Kamposioras, O. Aziz, J. Barriuso
Journal: Annals of Oncology (2023)
P-401 The promising role of TGF-βRII mutations and EGFR immunostaining in response to anti-EGFR therapies
Authors: A. Jaballah-Gabteni, F. Letaief-Ksontini, S. Ben Nasr, I. Ben Ayed, A. Dridi, H. Yaïche, N. Ben Jemii, D. Wider, M. Ardhaoui, A. Maaloul, E. Habbachi, A. Haddauoi, S. Boubaker, A. Mezlini, H. Guettiti Tounsi-Kettiti
Journal: Annals of Oncology (2023)
P-215 06-methylguanine DNA methyltransferase deficiency and outcomes with CAPTEM in patients with pancreatic neuroendocrine tumours
Authors: E. Terán Brage, J. Feito Pérez, M. Navarro Martín, R. Escala Cornejo, R. Vidal Tocino, B. Cigarral García, S. Del Carmen Martínez, N. Martín Gutiérrez, E. Fonseca Sánchez
Journal: Annals of Oncology (2023)
P-205 Streamlining the diagnostic pathway for Lynch syndrome in colorectal cancer patients: A ten-year experience in a single Italian center
Authors: A. Puccini, S. Nardin, L. Trevisan, S. Lastraioli, I. Ricciotti, A. Damiani, G. Bregni, A. Pastorino, V. Martelli, R. Murialdo, V. Gismondi, L. Battistuzzi, L. Varesco, M. Dono, F. Grillo, S. Sciallero
Journal: Annals of Oncology (2023)
P-63 Real-world UK retrospective multi-centre review of the use of G-CSF in the prevention of chemotherapy-induced neutropenia in patients with CRC receiving trifluridine/tipiracil
Authors: I. Purcell, H. Brooks, S. Gangadhara, V. Kunene, P. Teo, M. Malik, L. Bell, V. Potter
Journal: Annals of Oncology (2023)
LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)
Authors: A. Bullock, M. Fakih, M. Gordon, A. Tsimberidou, A. El-Khoueiry, B. Wilky, A. Pimentel, K. Margolin, D. Mahadevan, A. Balmanoukian, R. Sanborn, G. Schwartz, G. Abou-Alfa, B. Bockorny, J. Moser, S. Sharma, J. Grossman, K. Rosenthal, S. O'Day, H. Lenz, B. Schlechter
Journal: Annals of Oncology (2023)
PD-23 Comprehensive survey of AACR GENIE cBioPortal database of receptor tyrosine kinase fusion in colorectal carcinoma identified high co-occurring genomic alterations in NTRK1 &amp; RET fusion-positive CRC
Authors: A. Lee, Z. Arter, M. Cho, M. Nagasaka, S. Ou
Journal: Annals of Oncology (2023)